Clinical Trial Update: A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study to determine how PF-04776548 is cleared from the body after a micro-dose, using a radiotracer to quantify very low concentrations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• PF-04776548

Snippet

Sponsor: Pfizer | Conditions: Human Immunodeficiency Virus (HIV) | Phase 1 | Status: COMPLETED